Imfinzi and Lynparza in Advanced Endometrial Cancer
Medical Supporter — Informationshinweis
Dieser Artikel ist eine Zusammenfassung internationaler medizinischer Informationen und stellt keine medizinische Beratung dar; er ersetzt nicht die Diagnose oder den Behandlungsplan Ihres behandelnden Arztes. Die dargestellten Informationen stammen aus öffentlichen Veröffentlichungen und offiziellen Angaben führender japanischer medizinischer Einrichtungen; Eignung und Wirkung einer Therapie sind individuell und müssen von einem qualifizierten Arzt beurteilt werden.
Imfinzi and Lynparza in Advanced Endometrial Cancer
- June 7, 2023
- Reading time: 1 minute
On May 26, 2023, AstraZeneca announced significant results from the Phase 3 DUO-E clinical trial evaluating patients with advanced or recurrent endometrial cancer.
Study Design: The DUO-E trial evaluated patients receiving Imfinzi (durvalumab) in combination with platinum-based chemotherapy or chemotherapy alone as first-line treatment. Following the initial phase, patients received maintenance therapy with either Imfinzi plus Lynparza (olaparib) or Imfinzi monotherapy.
Clinical Outcomes: The results demonstrated that both maintenance regimens were superior to standard chemotherapy, resulting in a significant prolongation of progression-free survival (PFS). The combination of Imfinzi and Lynparza was particularly noted for providing substantial clinical benefit. While overall survival (OS) data is still maturing, a positive trend toward improved OS was observed in both treatment arms.
Safety Profile: The safety and tolerability profile was consistent with the known side effects of each individual agent observed in previous clinical evaluations. Detailed findings from the trial are expected to be presented at an upcoming medical congress.
Source: AstraZeneca Press Release.
- Clinical Trial Medications
- Immunotherapy
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Behandlung in Japan im Blick? Brauchen Sie Informationen und Unterstützung?
Wir helfen Ihnen, die für eine medizinische Reise nach Japan nötigen Informationen zu ordnen, kontaktieren japanische Einrichtungen und organisieren eine Zweitmeinungsberatung.Die Erstberatung ist kostenlos; ein Berater hilft Ihnen, die nächsten Schritte zu klären.
Figure 1
Figure 2
Figure 3
Figure 4